Ade LLC Sells 984 Shares of Pfizer Inc. (NYSE:PFE)

Ade LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 7.4% in the 1st quarter, HoldingsChannel reports. The fund owned 12,329 shares of the biopharmaceutical company’s stock after selling 984 shares during the quarter. Ade LLC’s holdings in Pfizer were worth $342,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in PFE. GoalVest Advisory LLC grew its holdings in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares in the last quarter. Creekmur Asset Management LLC bought a new stake in Pfizer in the 4th quarter valued at $32,000. Trivant Custom Portfolio Group LLC boosted its holdings in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. VisionPoint Advisory Group LLC increased its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new position in Pfizer during the 4th quarter valued at approximately $36,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.6 %

NYSE PFE opened at $27.98 on Monday. The firm has a market cap of $158.55 billion, a PE ratio of -466.26, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The company has a 50 day moving average price of $27.90 and a 200 day moving average price of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.23 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.00%. The ex-dividend date is Thursday, July 25th. Pfizer’s dividend payout ratio is presently -2,799.53%.

Analyst Ratings Changes

Several analysts recently weighed in on the company. BMO Capital Markets restated an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley lifted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, June 26th. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $35.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.